Safety and efficacy of anti-programmed death 1 antibodies in patients with cancer and pre-existing autoimmune or inflammatory disease.
Danlos FX, Voisin AL, Dyevre V, Michot JM, Routier E, Taillade L, Champiat S, Aspeslagh S, Haroche J, Albiges L, Massard C, Girard N, Dalle S, Besse B, Laghouati S, Soria JC, Mateus C, Robert C, Lanoy E, Marabelle A, Lambotte O.
Danlos FX, et al. Among authors: routier e.
Eur J Cancer. 2018 Mar;91:21-29. doi: 10.1016/j.ejca.2017.12.008. Epub 2018 Jan 10.
Eur J Cancer. 2018.
PMID: 29331748